Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
11:30am, Tuesday, 18'th Feb 2025
Teva Pharmaceutical Industries (TEVA) and partner Alvotech (ALVO) said the Food and Drug Administration (FDA) agreed to review their AVTO6 treatment for eye disorders.
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for
Teva Pharm CEO calls for faster US generic drug approvals
04:42am, Monday, 17'th Feb 2025
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding freezes, the CEO of Israel's Teva Pharmaceutical Industries said on Monday.
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
05:20pm, Tuesday, 11'th Feb 2025
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvel
On Monday, Axsome Therapeutics, Inc. AXSM signed a settlement agreement with Teva Pharmaceuticals Inc TEVA.
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
02:00am, Monday, 10'th Feb 2025
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE.
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
11:00am, Monday, 03'rd Feb 2025
Teva Pharmaceuticals Industries Ltd NYSE: TEVA is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a li
Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
01:35pm, Thursday, 30'th Jan 2025
Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be outperform
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
12:16pm, Thursday, 30'th Jan 2025
Teva stock falls 14% despite better-than-expected fourth-quarter earnings results due to a weak 2025 outlook.
Why Teva Pharmaceutical Stock Is Sinking Today
02:26pm, Wednesday, 29'th Jan 2025
Shares of Teva Pharmaceutical Industries (TEVA -13.21%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m.
Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet
01:39pm, Wednesday, 29'th Jan 2025
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1% on Wednesday.
Teva Pharma CEO: Guidance based on the new Teva that grows every year
12:24pm, Wednesday, 29'th Jan 2025
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug price negotiations, and much more.
Teva Pharmaceutical Industries Limited (TEVA) Q4 2024 Earnings Conference Call Transcript
12:02pm, Wednesday, 29'th Jan 2025
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q4 2024 Earnings Conference Call January 29, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say
10:31am, Wednesday, 29'th Jan 2025
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics
Teva Pharm Q4 tops estimates on strong sales of its own drugs
07:19am, Wednesday, 29'th Jan 2025
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington'
